Table 1.
Baseline characteristics in thromboembolic events and non‐thrombotic event groups. Values are median (IQR [range]) or number (proportion).
| Variables |
All patients n = 188 |
Thrombotic events n = 21 |
Non‐thrombotic events n = 167 |
p value |
|---|---|---|---|---|
| Age; years | 49 (40–61 [22–102]) | 50 (36–54 [31–84]) | 49 (40–62 [22–102]) | 0.42 |
| Male | 154 (82%) | 18 (86%) | 136 (81%) | 0.63 |
| BMI; kg.m−2 | 26.4 (24.0–30.5 [14.6–54.1]) | 26.0 (23.3–30.1 [18.2–34.3]) | 26.5 (24.1–30.5 [14.6–54.1]) | 0.30 |
| Any comorbidities | 118 (63%) | 12 (57%) | 106 (64%) | 0.52 |
| Diabetes mellitus | 73 (39%) | 7 (33%) | 66 (40%) | 0.64 |
| Hypertension | 76 (41%) | 8 (38%) | 68 (41%) | 0.82 |
| Chronic artery disease | 22 (12%) | 1 (5%) | 21 (13%) | 0.48 |
| Chronic kidney disease | 23 (12%) | 1 (5%) | 22 (13%) | 0.48 |
| Malignancy | 8 (4%) | 2 (10%) | 6 (4%) | 0.22 |
| Reasons for ICU admission; n (%) | ||||
| Acute respiratory distress syndrome | 143 (76%) | 17 (81%) | 126 (75%) | 0.85 |
| Other | 45 (24%) | 4 (19%) | 41 (25%) | |
| Laboratory data on ICU admission | ||||
| C‐reactive protein; mg.l‐1 | 110 (43–204 [0–509]) | 107 (21–221 [5–509]) | 111 (43–204 [0–479]) | 0.97 |
| Leucocytes count; × 109.l‐1 | 8.8 (6.3–12.1 [2.1–30.4]) | 9.5 (6.7–14.8 [3.2–30.4]) | 8.8 (6.2–12.2 [2.1–25.0]) | 0.50 |
| Lymphocytes count; ×109.l‐1 | 0.9 (0.6–1.3 [0.1–6.0) | 0.9 (0.5–1.4 [0.1–2.7]) | 0.9 (0.6–1.3 [0.1–6.0]) | 0.90 |
| Lymphocytes ≤ 1 × 109.l‐1; | 111 (59%) | 13 (65%) | 98 (59%) | 0.56 |
| Platelet count; ×109.l‐1 | 226 (174–285 [60–548]) | 246 (181–310 [128–482]) | 226 (173–285 [60–548]) | 0.55 |
| INR | 1.2 (1.1–1.3 [0.9–10]) | 1.2 (1.1–1.3 [0.9–1.3]) | 1.2 (1.1–1.3 [0.9–10]) | 0.70 |
| Activated partial thromboplastin time; s | 34 (30–38) [23–179]) | 31 (28–38 [24–59]) | 34 (30–38 [23–179]) | 0.40 |
| D‐dimer; µg.ml‐1 [normal reference:<0.05] | 1.8 (0.8–3.9 [0.3–4.0]) | 4.0 (1.8–4.0 [0.5–4.0]) | 1.5 (0.8–3.5 [0.3–4.0]) | 0.004 |
| D‐dimer (max); µg.ml‐1 | 3.5 (1.3–4.0 [0.3–4.0]) | 4.0 (4.0–4.0 [0.5–4.0]) | 3.0 (1.2–4.0 [0.3–4.0]) | <0.001 |
| D‐dimer (max) >3 µg.ml‐1 | 97/179 (52%) | 18/21 (86%) | 79/158 (50%) | 0.002 |
| Fibrinogen; g.l‐1 | 6.0 (4.5–7.1 [0.8–8.0]) | 5.4 (2.3–6.7 [1.5–8.0]) | 6.0 (4.7–7.2 [0.8–8.0]) | 0.22 |
| Ferritin; µg.l‐1 [reference range: 36–480] | 995 (494–1904 [30–8000]) | 843 (529–2333 [180–3625]) | 1009 (492–1809 [30–8000]) | 0.70 |
| Interleukin‐6; ng.l‐1 | 155 (54–620 [2–10748]) | 668 (45–2264 [15–10748]) | 153 (55–437 [2–7946]) | 0.25 |
| ICU treatments | ||||
| Invasive mechanical ventilation | 98 (52%) | 15 (71%) | 83 (50%) | 0.06 |
| Extracorporeal membrane oxygenation | 9 (5%) | 3 (14%) | 6 (4%) | 0.065 |
| Thromboprophylaxis strategy | ||||
| None | 6 (3%) | 0 | 6 (4%) | 0.46 |
| Standard prophylactic dose | 83 (44%) | 11 (52%) | 72 (43%) | |
| High‐intensity prophylactic dose | 75 (40%) | 6 (29%) | 69 (41%) | |
| Therapeutic anticoagulation | 24 (13%) | 4 (19%) | 20 (12%) | |
| ICU outcomes | ||||
| ICU mortality | 38 (20%) | 5 (24%) | 33 (20%) | 0.77 |
| Duration of mechanical ventilation, day | 14 (7–29 [1–81]) | 16 (10–32 [1–74]) | 13 (6–28 [1–81]) | 0.24 |
| ICU length of stay, days | 9 (5–21 [2–75]) | 20 (8–30 [3–74]) | 9 (5–19 [2–75]) | 0.01 |